| アブストラクト | Aim: We aimed to systematically characterize ear and labyrinth toxicities after immune checkpoint inhibitors (ICIs) initiation. Materials & methods: Data were extracted from the US FDA Adverse Event Reporting System database. Disproportionality analysis including information component and reporting odds ratio (ROR) was performed to access potential signals. Results: In FDA Adverse Event Reporting System database, 284 records for ICIs-associated ear/labyrinth adverse events (AEs) were involved. In general, there was no significant association between total ICIs use and total ear and labyrinth AEs (ROR025: 0.576). However, in ICIs monotherapy and polytherapy groups, signals were detected in several specific ear and labyrinth AEs. Conclusion: Total ear and labyrinth toxicities were not significantly reported with ICI immunotherapy, while class-specific ear toxicities were detected in some strategies. |
|---|
| ジャーナル名 | Immunotherapy |
|---|
| Pubmed追加日 | 2020/5/28 |
|---|
| 投稿者 | Hu, Fangyuan; Ye, Xiaofei; Zhai, Yinghong; Xu, Jinfang; Guo, Xiaojing; Guo, Zhijian; Zhou, Xiang; Ruan, Yiming; Zhuang, YongLong; He, Jia |
|---|
| 組織名 | Department of Health Statistics, Second Military Medical University, Shanghai,;China.;Tongji University School of Medicine, Shanghai, China.;Beijing Bioknow Information Technology Co. Ltd, Beijing, China. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/32456497/ |
|---|
